share_log

On Point Legal Leads Releases In-Depth Guide on Depo-Provera Litigation and Controversial Safety Warnings

On Point Legal Leads Releases In-Depth Guide on Depo-Provera Litigation and Controversial Safety Warnings

On Point Legal Leads發佈關於Depo-Provera訴訟和有爭議的安全警告的詳細指南
PR Newswire ·  11/20 21:47

DALLAS, Nov. 20, 2024 /PRNewswire/ -- On Point Legal Leads, a leading provider of mass tort leads and signed intake retainers, is excited to announce the launch of its latest comprehensive guide, Depo-Provera: Litigation Controversial Safety Warnings.

達拉斯,2024年11月20日 /PRNewswire/ -- 領先的大規模侵權索賠線索和簽署保留意向書提供商On Point Legal Leads,很高興宣佈推出最新的綜合指南,Depo-Provera: 訴訟爭議安全警告。

This in-depth analysis sheds light on the critical health and legal issues surrounding Depo-Provera, empowering legal professionals, patients, and industry stakeholders with essential information.

這一深入分析闡明瞭圍繞Depo-Provera的關鍵健康和法律問題,爲法律專業人士、患者和行業利益相關者提供了必要的信息。

Depo-Provera Litigation: Controversial Safety Warnings
Depo-Provera 訴訟:爭議安全警告

The guide provides extensive insights into:

該指南提供了廣泛的見解:

  • The health risks associated with Depo-Provera, including a significant increase in meningioma risk as highlighted by recent studies.
  • Disparities in Pfizer's international safety warnings, including meningioma risk information provided in Europe and Canada but not in the U.S.
  • The expected scope of litigation, with projections for Multidistrict Litigation (MDL) in 2025 involving an estimated 30,000 cases.
  • Depo-Provera相關的健康風險,包括最近研究突出的腦膜瘤風險顯著增加。
  • 輝瑞在國際範圍內不同地區的安全警告存在差異,包括在歐洲和加拿大提供腦膜瘤風險信息,但在美國沒有提供。
  • 該指南預計訴訟範圍,預測2025年將涉及估計爲3萬起案件的多區訴訟(MDL)。

Key findings from the guide include:

該指南的關鍵發現包括:

  • Depo-Provera users are 5.55 times more likely to develop meningiomas than non-users, according to a 2024 British Medical Journal study.
  • Since its FDA approval in 1992, Depo-Provera has been used by over a quarter of sexually active women in the U.S., underscoring its widespread reach.
  • Ongoing legal cases focus on Pfizer's alleged failure to warn U.S. consumers of the risks, despite having issued warnings in other countries.
  • 根據2024年英國醫學雜誌的研究,使用Depo-Provera的用戶患腦膜瘤的可能性是非用戶的5.55倍。
  • 自1992年獲得FDA批准以來,Depo-Provera已被美國四分之一以上的有性行爲的婦女使用,突顯其廣泛影響力。
  • 正在進行的法律案件集中在輝瑞公司被指責未能警告美國消費者風險,儘管已在其他國家發佈警告。

Robert Wilson, President and Founder of On Point Legal Leads, commented on the urgency of the issue: "As we uncover more about the health impacts of Depo-Provera, it's crucial that affected individuals have access to accurate information and strong legal representation. This guide is a valuable resource for those seeking justice and transparency in their healthcare options."

On Point Legal Leads總裁兼創始人羅伯特·威爾遜就這一問題的緊急性發表了評論:「隨着我們對Depo-Provera健康影響的了解越來越多,受影響的個人有權獲得準確信息和強大的法律代理。本指南對於那些在尋求公正和透明的醫療選擇中尋求正義的人來說是一種有價值的資源。」

The report also explores the potential long-term effects and substantial medical costs faced by those diagnosed with meningiomas after using Depo-Provera, underscoring the need for heightened awareness and proactive legal support.

該報告還探討了使用Depo-Provera後被診斷患有腦膜瘤的人面臨的潛在長期影響和巨額醫療費用,突顯了加強意識和積極法律支持的必要性。

Emerging Legal and Healthcare Trends

新興的法律和醫療趨勢

The guide provides a forward-looking perspective on trends shaping the future of Depo-Provera litigation, including:

該指南展示了對塑造Depo-Provera訴訟未來趨勢的前瞻性觀點,包括:

  • Anticipated expansion in litigation, as legal experts project a substantial increase in cases over the next year.
  • The importance of transparent safety communications and accountability in the pharmaceutical industry.
  • Steps for current and former Depo-Provera users to assess their health risks and protect their legal rights.
  • 隨着法律專家預測未來一年案件數量將大幅增加,訴訟預計會擴大。
  • 在藥品行業中,透明度安全通信和問責制的重要性。
  • 現有和以前使用Depo-Provera的用戶可採取措施評估其健康風險並保護其法律權利。

"At On Point Legal Leads, we're committed to advancing access to critical information and facilitating legal connections for those impacted by Depo-Provera," Mr. Wilson added. "This guide is part of our ongoing mission to support law firms in meaningful, impactful ways as they navigate this complex area of mass tort litigation."

“在On Point Legal Leads,我們致力於推動對關鍵信息的獲取,併爲受Depo-Provera影響的人士提供法律聯繫。“威爾遜先生補充說。「這份指南是我們持續使命的一部分,支持律師事務所以有意義、有影響力的方式應對這一大規模侵權訴訟複雜領域。」

Access the Full Guide on Depo-Provera and Learn More

訪問關於Depo-Provera的完整指南並了解更多信息

The complete guide, Depo-Provera Litigation: Controversial Safety Warnings, is available now on the On Point Legal Leads website.

完整指南《Depo-Provera訴訟:備受爭議的安全警告》現在可在On Point Legal Leads網站上獲取。

For additional information on Depo-Provera mass tort leads and signed retainers, please visit:

有關Depo-Provera大規模侵權索賠和簽訂保留權額外信息,請訪問:

About On Point Legal Leads:

關於On Point Legal Leads:

Founded in 2016, On Point Legal Leads is a trusted provider of high-quality legal leads and intake services across the United States. Specializing in mass torts, personal injury, workers' compensation, and more, On Point Legal Leads delivers targeted, real-time leads to help law firms connect with clients seeking legal representation.

成立於2016年,On Point Legal Leads是美國一家備受信賴的高質量法律引線和接待服務提供商。專業從事大規模侵權訴訟、人身傷害、工傷賠償等領域,On Point Legal Leads提供定向、實時的線索,幫助律師事務所與尋求法律代表的客戶取得聯繫。

For more information, visit:

請訪問:

Media Contact:

媒體聯繫:

Robert Wilson

Robert Wilson

9723335114

9723335114

[email protected]

[email protected]

SOURCE On Point Legal Leads

SOURCE On Point Legal Leads

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎?

440k+
440k+

Newsrooms &
新聞發佈室&

Influencers
影響力人士
9k+
9k+

Digital Media
數字媒體

Outlets
Outlets
270k+
270k+

Journalists
記者

Opted In
Opted In
GET STARTED
開始使用

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論